by Jason Heaviland | Mar 2, 2026
Chemical Exposure Profiling of Alzheimer’s Patients This webinar presents a comprehensive overview of chemical exposure profiling in Alzheimer’s patients using Panome Bio’s Targeted Exposomics™ and Discovery Exposomics™ platforms. Learn how quantitative exposure...
by Jason Heaviland | Feb 27, 2026
Discovery Exposomics profiling of 30 serum samples identified 240 exposure chemicals, with 138 showing significant differences between Alzheimer’s disease and healthy control groups. The analysis revealed distinct exposure patterns and enrichment across chemical...
by Jason Heaviland | Feb 27, 2026
Targeted Exposomics profiling of 30 serum samples revealed distinct chemical exposure patterns associated with Alzheimer’s disease. Twenty-nine chemical exposures were detected, with several showing significant differences between Alzheimer’s disease and control...
by Jason Heaviland | Feb 27, 2026 | Uncategorized
For 20 years, genomics has promised precision medicine. And it delivered. For rare diseases and select cancers. But for most chronic conditions?
Genetics explains only a fraction of risk. Type 2 diabetes. Alzheimer’s disease. Autoimmune disorders. Metabolic syndrome....
